Stock Analiz

Kairos Pharma, LTD. KAPA

Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026

$0.45Market cap $2M
Open the interactive analysis →

Kairos Pharma, LTD. (KAPA) is a healthcare company listed in the US with a market value of about $2M.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.8, a 5-year average ROIC of -54%.

About Kairos Pharma, LTD.

Kairos Pharma, LTD. is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data.

Score: 1.2 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.8
Forward P/E—
P/FCF—
P/S—
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-54.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal year202520242023
Revenue———
Net income-$5M-$3M-$2M
Free cash flow——$81000
EPS (diluted)$-0.30$-0.23$-0.17
Net margin———
ROIC-69.4%-38.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $49.00, 10703% above the current price; targets range from $14.00 to $84.00; the consensus rating is “Strong buy”; expected EPS is $-2.59 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Kairos Pharma, LTD.’s P/E ratio?

About 0.8, based on the last twelve months of diluted earnings per share.

Does Kairos Pharma, LTD. pay a dividend?

Not currently.

Is Kairos Pharma, LTD. a good stock to buy?

We do not give buy or sell advice. Kairos Pharma, LTD. scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.